Evaluate Vantage Homepage
Pepgen aims to overtake Sarepta
Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.
Big pharma’s key fourth-quarter data
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
Ocular Therapeutix joins the long-acting race
But the group has a long way to go to set up a showdown with Eylea.
Medtech
Ember burns bright for Angle
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.
TCT 2022 – Otsuka’s renal denervation system shines
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
Company Events
Fourth-quarter data for the little guys
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Go or no go? GSK takes its turn with a novel anaemia class
Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.
Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Interviews
Pepgen aims to overtake Sarepta
Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.
T3D puts a bet on Alzheibetes
An unusual update at last month’s AAIC meeting puts the focus on a phase 2 readout next year, but time might be running out.
Novo’s cardiovascular and rare disease charge continues
Before the Forma deal Novo brought in assets via Corvidia, Prothena and Heartseed. Some have progressed faster than others.